Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 3.1.6.2 - steryl-sulfatase and Organism(s) Homo sapiens and UniProt Accession P08842

for references in articles please use BRENDA:EC3.1.6.2
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
     3 Hydrolases
         3.1 Acting on ester bonds
             3.1.6 Sulfuric-ester hydrolases
                3.1.6.2 steryl-sulfatase
IUBMB Comments
Also acts on some related steryl sulfates.
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Homo sapiens
UNIPROT: P08842
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Homo sapiens
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
Synonyms
dheas, steroid sulfatase, steroid sulphatase, estrone sulfatase, arylsulfatase c, e1-sts, sterol sulfatase, dehydroepiandrosterone sulfatase, steryl-sulfatase, arylsufatase, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
steroid sulfatase
-
3-beta-hydroxysteroid sulfate sulfatase
-
-
-
-
arylsufatase
-
-
arylsulfatase C
-
-
-
-
ASC
-
-
-
-
cholesterol sulfate sulfohydrolase
-
-
CHS-ase
-
-
dehydroepiandrosterone sulfatase
-
-
-
-
dehydroepiandrosterone sulfate sulfatase
-
-
-
-
DHEAS
-
-
estrone sulfatase
-
-
phenolic steroid sulfatase
-
-
-
-
pregnenolone sulfatase
-
-
-
-
steroid 3-sulfatase
-
-
-
-
steroid sulfatase
steroid sulfate sulfohydrolase
-
-
-
-
steroid sulphatase
-
-
sterol sulfatase
-
-
-
-
sterolsulfate sulfohydrolase
-
-
Steryl-sulfate sulfohydrolase
-
-
-
-
sulfatase, sterol
-
-
-
-
additional information
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of sulfuric ester
-
-
-
-
PATHWAY SOURCE
PATHWAYS
SYSTEMATIC NAME
IUBMB Comments
steryl-sulfate sulfohydrolase
Also acts on some related steryl sulfates.
CAS REGISTRY NUMBER
COMMENTARY hide
9025-62-1
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
17beta-estradiol sulfate + H2O
17beta-estradiol + sulfate
show the reaction diagram
-
-
-
?
4-methylumbelliferyl sulfate + H2O
4-methylumbelliferone + sulfate
show the reaction diagram
-
-
-
?
cholesterol 3-sulfate + H2O
cholesterol + sulfate
show the reaction diagram
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
show the reaction diagram
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
show the reaction diagram
estrone 3-sulfate + H2O
estrone + sulfate
show the reaction diagram
-
-
-
?
estrone sulfate
estrone + sulfate
show the reaction diagram
-
-
-
?
estrone sulfate + H2O
estrone + sulfate
show the reaction diagram
pregnenolone 3-sulfate + H2O
pregnenolone + sulfate
show the reaction diagram
-
-
-
?
16alpha-hydroxydehydroepiandrosterone 3-sulfate + H2O
16alpha-hydroxydehydroepiandrosterone + sulfate
show the reaction diagram
-
-
-
-
?
17beta-estradiol sulfate + H2O
17beta-estradiol + sulfate
show the reaction diagram
-
-
-
-
?
3beta-hydroxyandrost-5-en-17-one 3-sulfate + H2O
3beta-hydroxyandrost-5-en-17-one + sulfate
show the reaction diagram
-
-
-
-
?
4-methylumbelliferyl sulfate + H2O
4-methylumbelliferol + sulfate
show the reaction diagram
-
-
-
-
?
4-methylumbelliferyl sulfate + H2O
4-methylumbelliferone + sulfate
show the reaction diagram
4-methylumbelliferyl-6-O-sulfate + H2O
4-methylumbelliferone + sulfate
show the reaction diagram
-
-
-
-
?
7-dehydroepiandrosterone sulfate + H2O
7-dehydroepiandrosterone + sulfate
show the reaction diagram
-
-
-
-
?
androstenediol 3-sulfate + H2O
androstenediol + sulfate
show the reaction diagram
-
-
-
-
?
androstenediol sulfate + H2O
androstenediol + sulfate
show the reaction diagram
-
-
-
-
?
androstenediol-3-sulfate + H2O
androstenediol + sulfate
show the reaction diagram
-
-
-
-
?
arzoxifene sulfate + H2O
arzoxifene + sulfate
show the reaction diagram
-
product of sulfotransferase reaction on arzoxifene used in hormone replacement therapy
-
-
?
cholesterol 3-sulfate + H2O
cholesterol + sulfate
show the reaction diagram
cholesterol sulfate + H2O
cholesterol + sulfate
show the reaction diagram
dehydroandrosterone 3-sulfate + H2O
dehydroandrosterone + sulfate
show the reaction diagram
-
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
show the reaction diagram
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
show the reaction diagram
dehydroisoandrosterone 3-sulfate + H2O
dehydroisoandrosterone + sulfate
show the reaction diagram
-
-
-
-
?
estrone 3-sulfate + H2O
estrone + sulfate
show the reaction diagram
estrone sulfate + H2O
estrone + sulfate
show the reaction diagram
p-nitrophenyl-sulfate + H2O
p-nitrophenol + sulfate
show the reaction diagram
-
arylsulfatase activity, EC 3.1.6.1, and various steroid sulfatase activities (EC 3.1.6.1) are functions of the same protein
-
-
?
pregnenolone sulfate + H2O
pregnenolone + sulfate
show the reaction diagram
raloxifene sulfate + H2O
raloxifene + sulfate
show the reaction diagram
-
product of sulfotransferase reaction on raloxifene used in hormone replacement therapy, the benzothiophene sulfate is substrate, the 4'-phenolic sulfate is no substrate for enzyme
-
-
?
steroid sulfate + H2O
steroid + sulfate
show the reaction diagram
-
-
-
-
?
steroid sulfates + H2O
steroid + sulfate
show the reaction diagram
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
-
-
?
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
show the reaction diagram
in adipose tissue, further concersion to bioactive androgens and estrogens
-
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
show the reaction diagram
estrone sulfate
estrone + sulfate
show the reaction diagram
-
-
-
?
estrone sulfate + H2O
estrone + sulfate
show the reaction diagram
cholesterol sulfate + H2O
cholesterol + sulfate
show the reaction diagram
-
cholesterol sulfate metabolism, steroid sulfohydrolase pathway
-
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
show the reaction diagram
estrone 3-sulfate + H2O
estrone + sulfate
show the reaction diagram
-
hydrolyzes estrone 3-sulfate to its active, unsulfated form
-
-
?
estrone sulfate + H2O
estrone + sulfate
show the reaction diagram
steroid sulfate + H2O
steroid + sulfate
show the reaction diagram
-
-
-
-
?
steroid sulfates + H2O
steroid + sulfate
show the reaction diagram
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Ca2+
10 mM, about 120% of initial activity
Mg2+
10 mM, about 120% of initial activity
Mn2+
10 mM, about 115% of initial activity
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(R)-1-[(4-cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
pure R(+)-enantiomer of 1-[(4-Cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
(S)-1-[(4-cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
pure S(-)-enantiomer of 1-[(4-Cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
1-[(4-cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
bromo derivative of 1-[(4-cyanophenyl)(3-chloro-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole does improve aromatase inhibitory activity
1-[(4-cyanophenyl)(3-chloro-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
meta-chloro derivative of 1-[(4-cyanophenyl)(4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole does increase aromatase inhibition activity
1-[(4-cyanophenyl)(4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
increase of aromatase inhibitory activity due to presence of a para-cyanophenyl moiety
1-[bis-(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
best dual inhibition
1-[bis-(3-sulfamoyloxy-4-methoxyphenyl)methyl]-1H-[1,2,4]triazole
methoxy groups reduce inhibition of aromatase compared to 1-[bis-(3-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
1-[bis-(3-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
sulfamate in meta-position increases aromatase inhibition strength compared to para-position
1-[bis-(4-sulfamoyloxy-3-methoxyphenyl)methyl]-1H-[1,2,4]triazole
exchange in positions of methoxy and sulfamate group compared to 1-[bis-(3-sulfamoyloxy-4-methoxyphenyl)methyl]-1H-[1,2,4]triazole fails to improve aromatase inhibitory activity
2-chloro-4-[5-(2,6-difluoro-3-hydroxybenzoyl)thiophen-2-yl]phenyl sulfamate
dual inhibitor, acts both on STS and hydroxy steroid dehydrogenase 17beta-HSD1, reverses estrogen-induced T-47D cell proliferation
3-sulfamoyloxy-N-3,3,3-trifluoropropyl-16,17-seco-estra-1,3,4(10)-triene-16,17-imide
highly potent, long-acting, nonestrogenic steroid sulfatase inhibitor with inhibitory properties to human carbonic anhydrase II, thus enabling transport by erythorcytes, no estrogenic effects observed in uterine weight gain study with ovariectomized Wistar rats, 24 h after last dose of 4 days of oral administration of 10 mg/kg/d, in vivo: single dose of 0.1 mg/kg 48% inhibition of liver steroid sulfatase activity, 0.5 and 1 mg/kg total inhibition, activity measured 24 h after dose administration, recovery of steroid sulfatase acitivity after single oral dose of 10 mg/kg: complete inhibition till day 5, day 17: 50% recovery, day 28: complete recovery
3-[4-(3,4-difluoro-benzoylamino)-phenyl]-coumarin-7-O-sulfamate
compound exhibits poor cytotoxicity
3-[4-[2-(2,5-bis-trifluoromethyl-phenyl)-acetylamino]-phenyl]-coumarin-7-O-sulfamate
compound shows antiproliferative activity against the MCF-7 and T47D cell lines, GI50 value is 15.9 microM and 8.7 microM, respectively
4-(cyclohexanecarboxamido)phenyl sulfamate
55.7% inhibition of isolated enzyme at 0.01 mM, 86.1% inhibition of the STS activity of JEG-3 carcinoma cells at 0.010 mM
4-fluoro-17beta-(3'-trifluoromethylbenzene)sulfonamideestra-1,3,5(10)-trien-3-ol
-
4-nitro-17beta-4'-biphenylsulfonamide-1,3,5(10)-estratrien-3-ol
-
dexamethasone
inhibits STS activity and expression in undifferentiated cells, the glucocorticoid antagonist RU486 reverses dexamethasone inhibition of STS
Fe2+
10 mM, about 40% of initial activity
irosustat
-
STX213
highly potent, long-acting, nonestrogenic steroid sulfatase inhibitor with inhibitory properties to human carbonic anhydrase II, thus enabling transport by erythorcytes, no estrogenic effects observed in uterine weight gain study with ovariectomized Wistar rats, 24 h after last dose of 4 days of oral administration of 10 mg/kg/d, in vivo: single dose of 0.1 mg/kg 25% inhibition of liver steroid sulfatase activity, 0.5 and 1 mg/kg total inhibition, activity measured 24 h after dose administration, recovery of steroid sulfatase acitivity after single oral dose of 10 mg/kg: complete inhibition till day 4, day 12: 50% recovery, day 15: almost complete recovery
STX64
synonym BN83495, irreversible inhibition, STS inhibitor property within dual aromatase-sulfatase inhibitor, letrozole reversible cytochrome P450 enzyme aromatase inhibitor serves as aromatase inhibiting component
Zn2+
10 mM, loss of activity
(12aS)-N,N-dihydroxy-12a-methyl-1,3-dioxo-2-propyl-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho[2,1-f]isoquinoline-8-sulfinamide
-
-
(17beta)-17-(2,3,4,5,6-pentafluorobenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(2-furylmethyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(3,5-dibromobenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(3-benzyloxybenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(3-bromobenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(3-iodobenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(3-tert-butylbenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(3-trifluoromethylbenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(4-bromobenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(4-iodobenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(4-methyl-2-thienyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(4-tert-butylbenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(4-tert-butylbenzyl)estra-1(10),2,4-triene-3,17-diol
-
estradiol phenolic reversible inhibitor as reference, possible additional breast cancer therapy, no inhibition at 0.01 microM, at 0.1 microM 39% inhibition, at 1 microM 62% inhibition
(17beta)-17-(4-trifluoromethylbenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(cyclohexylmethyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(cyclopropylmethyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(pyridin-3-ylmethyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-benzyl-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-benzylestra-1(10),2,4-triene-3,17-diol
-
estradiol phenolic reversible inhibitor as reference, possible additional breast cancer therapy, no inhibition at 0.01 microM, at 0.1 microM 15% inhibition, at 1 microM 48% inhibition
(17beta)-17-[3,5-bis(benzyloxy)benzyl]-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-[3,5-bis(tert-butyl)benzyl]-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-[3,5-bis(trifluoromethyl)benzyl]-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-[3-(dibenzylamino)benzyl]-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-[4-(benzyloxy)benzyl]-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-{[2-(2-bromoethyl)cyclopropyl]methyl}estra-1(10),2,4-triene-3,17-diol
-
-
(17beta,17'beta)-17,17'-(2E)-but-2-ene-1,4-diylbisestra-1(10),2,4-triene-3,17-diol
-
reversible non-competitive or mixed inhibition, estradiol dimer with C17-C17 bond, possible additional breast cancer therapy, no inhibition at 0.01 microM, at 0.1 microM 42% inhibition, at 1 microM 56% inhibition
(17beta,17'beta)-17,17'-butane-1,4-diylbisestra-1(10),2,4-triene-3,17-diol
-
reversible non-competitive or mixed inhibition, estradiol dimer with C17-C17 bond, possible additional breast cancer therapy, no inhibition at 0.01 microM, at 0.1 microM 30% inhibition, at 1 microM 54% inhibition
(2-(1-adamantyl)-4-oxo-4H-chromen-6-yl)(oxo)acetic acid
-
-
(2-(1-adamantyl)-4-oxo-4H-chromen-6-yl)acetic acid
-
-
(p-O-sulfamoyl)-N-tetradecanoyl tyramine
-
non-estrogenic STS inhibitor, IC50: 56 nM/l, anti-cancer activity
1-indanone 4-O-sulfamate
-
-
1-indanone 5-O-sulfamate
-
-
1-indanone 6-O-sulfamate
-
-
1-tetralone 6-O-sulfamate
-
-
1-tetralone 7-O-sulfamate
-
-
16alpha-hydroxydehydroepiandrosterone
-
competitive to dihydroepiandrosterone
17alpha-benzyl-17beta-hydroxyestra-1,3,5-(10)-triene-3-boronic acid
-
-
17alpha-benzyl-3,17beta-dihydroxyestra-1,3,5-(10)-triene
-
-
17beta estradiol
-
exposure to 17beta estradiol causes 70% reduction of estrone 3-sulfate sulfatase activity in MCF-7 cells after 6 days, but 9% increase in mammary myoepithelial cells
19,19-difluoro-17-oxo-4,9-cyclo-9,10-secoandrosta-1,3,5(10)-trien-1-yl hydrogen sulfate
-
-
19-fluoro-17-oxo-4,9-cyclo-9,10-secoandrosta-1,3,5(10)-trien-1-yl hydrogen sulfate
-
-
2',4'-dicyano-N,N-dihydroxybiphenyl-4-sulfinamide
-
-
2-(1-adamantyl)-4-oxo-4H-chromen-6-yl sulfamate
-
-
2-(1-adamantyl)-4-oxo-4H-chromene-6-carbaldehyde
-
-
2-(1-adamantyl)-4-oxo-4H-chromene-6-carboxamide
-
-
2-(1-adamantyl)-4-oxo-4H-chromene-6-carboxylic acid
-
-
2-(1-adamantyl)-4-oxo-4H-thiochromen-6-yl sulfamate
-
-
2-(1-adamantyl)-4-oxo-4H-thiochromene-6-carbonitrile
-
-
2-(1-adamantyl)-4-oxo-4H-thiochromene-6-carboxylic acid
-
-
2-(1-adamantyl)-6-(hydroxymethyl)-4H-chromen-4-one
-
-
2-(1-adamantyl)-6-glycoloyl-4H-chromen-4-one
-
-
2-(difluoromethyl)-17-oxoestra-1(10),2,4-trien-3-yl hydrogen sulfate
-
-
2-(fluoromethyl)-17-oxoestra-1(10),2,4-trien-3-yl hydrogen sulfate
-
-
2-bromo-4-[(R)-(4-cyanophenyl)(1H-1,2,4-triazol-1-yl)methyl]-N,N-dihydroxybenzenesulfinamide
-
-
2-formyl-17alpha-benzyl-17beta-hydroxyestra-1,3,5(10)-triene
-
time- and concentration-dependent inhibitor, shows more or less pseudo-first order behavior at all concentrations
2-methoxy-6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate
-
-
2-methoxyestrone-3-O-sulfamate
-
potent active site-directed inhibitor, no effect on STS mRNA expression in fibroblasts
2-phenylindole sulfamate
-
2-phenylindole sulfamates with lipophilic side chains in 1- or 5-position of the indole with IC50-values between 2 nM and 0.001 mM, irreversibly inhibits hydrolysis of estrone sulfate in MDA-MB 231 cells, inhibits gene activation in estrogen receptor-positive MCF-7 breast cancer cells in submicromolar concentrations and reduces cell proliferation with IC50 of 0.001 mM
2-t-butyl-4H-1-benzopyran-4-one-6-boronic acid
-
-
2-tert-butyl-6-hydroxy-4H-chromen-4-one
-
-
2-[3-[[(4-[[(aminooxy)sulfinyl]oxy]phenyl)sulfanyl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
-
-
2H1-benzpyran 7-O-disulfamate
-
-
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-4'-cyanobiphenyl-4-yl sulfamate
-
-
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-5'-(2-cyanopropan-2-yl)biphenyl-4-yl sulfamate
-
68.2% inhibition at 0.01 mM
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-5'-cyanobiphenyl-4-yl sulfamate
-
-
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chlorobiphenyl-4-yl sulfamate
-
-
3'-((1H-1,2,4-triazol-1-yl)methyl)-4'-cyanobiphenyl-4-yl sulfamate
-
-
3'-((1H-1,2,4-triazol-1-yl)methyl)biphenyl-4-yl sulfamate
-
-
3'-chloro-5-(1H-1,2,4-triazol-1-ylmethyl)biphenyl-2-carbonitrile
-
-
3,4,8-trimethylcoumarin 7-O-sulfamate
-
-
3,4-dihydro-4-methylcoumarin 7-O-sulfamate
-
-
3,4-dihydrocoumarin 7-O-sulfamate
-
-
3,4-dimethylcoumarin 7-O-sulfate
-
12-fold more potent than COUMATE
3-benzyl-4-methylcoumarin-7-O-sulfamate
-
IC50 value 0.68 nM in intact MCF-7 cells
3-hexyl-4-methylcoumarin-7-O-sulfamate
-
IC50 value 0.68 nM in intact MCF-7 cells
3-oxo-1,3-dihydro-2H-cyclobuta[c]chromen-6-yl sulfamate
-
-
4'-((1H-1,2,4-triazol-1-yl)methyl)-2'-cyanobiphenyl-4-yl sulfamate
-
-
4'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-2'-cyanobiphenyl-4-yl sulfamate
-
-
4-(((4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino)methyl)-2-methoxyphenyl sulfamate
-
-
4-(trifluoromethyl)coumarin 7-O-sulfamate
-
-
4-fluoro-17alpha-benzyl-17beta-hydroxyestra-1,3,5(10)-triene
-
linear mixed-type inhibition, compound is capable of binding at sites both within and outside the active site
4-methylcoumarin 6,7-O,O-disulfamate
-
-
4-methylcoumarin 7-O-sulfamate
-
COUMATE, also in vivo
4-oxo-1,2,3,4-tetrahydrocyclopenta[c]chromen-7-yl sulfamate
-
-
5'-((1H-1,2,4-triazol-1-yl)methyl)-2'-cyanobiphenyl-4-yl sulfamate
-
-
5'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-2'-cyanobiphenyl-4-yl sulfamate
-
-
5,6,7,8-tetrahydronaphthalene 2-O-(N,N-dimethyl)sulfamate
-
-
5,6,7,8-tetrahydronaphthalene 2-O-(N-methyl)sulfamate
-
-
5,6,7,8-tetrahydronaphthalene 2-O-sulfamate
-
-
5-(((4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino)methyl)-2-methoxyphenyl sulfamate
-
-
5-((1H-1,2,4-triazol-1-yl)methyl)-3'-chloro-4'-hydroxybiphenyl-2-carbonitrile
-
-
5-((1H-1,2,4-triazol-1-yl)methyl)-4'-hydroxybiphenyl-2-carbonitrile
-
-
5-methyl-6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
5-pregnen-3beta,21-diol
-
most potent inhibitor of C21 steroids
5-pregnen-3beta,21-diol-20-one
-
most potent inhibitor of C21 steroids
5alpha-androstane-3alpha-17beta-diol
-
most potent inhibitor of C19 steroids
6-(3-phenylpropoxy)-8,9,10,11-tetrahydro-7H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
6-(pentyloxy)-8,9,10,11-tetrahydro-7H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
6-methoxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
6-methoxycoumarin 7-O-sulfamate
-
-
6-oxo-5-(3-phenylpropyl)-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
6-oxo-5-pentyl-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11,12,13,14,15,16,17,18,19-tetradecahydrocyclopentadeca[c]chromen-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclotrideca[c]chromen-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11,12,13,14,15-decahydrocycloundeca[c]chromen-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11,12,13-octahydrocyclonona[c]chromen-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-ylsulfamide
-
-
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-2-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl dimethylsulfamate
-
-
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate
-
-
6-oxo-7,8,9,10,11,12,13,14,15,16-decahydro-6H-cyclododeca[c]-chromen-3-yl sulfamate
-
-
6-oxo-7,8,9,10,11,12,13,14-octahydro-6H-cyclodeca[c]chromen-3-yl sulfamate
-
-
6-oxo-7,8,9,10,11,12-hexahydro-6H-cycloocta[c]chromen-3-yl sulfamate
-
i.e. STW64, treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer. Inhibitor almost completely blocks enzyme activity in peripheral blood lymphocytes and tumor tissues, inhibition is associated with significant reductions in serum concentrations of androstenediol and estrogens. Serum androstenedione concentration also decreases by up to 86%
6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl sulfamate
-
-
6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulfamate
-
6,6,7-COUMATE, IC50: 5.1 nM in JEG-3 cells, 0.43 nM in MCF-7 cells
6-oxo-8,9,10,11-tetrahydro-7H-cylohepta-[c][1]benzopyran-boronic acid
-
-
667-coumate
-
-
7,8-dihydronaphthalene 2-O-sulfamate
-
-
7-hydroxy-4-methylcoumarin 6-O-sulfamate
-
-
AgNO3
-
5 mM, 65% inhibition
Ammonium molybdate
-
10 mM, 20% residual activity
anastrozole
-
-
breast cyst fluid
-
-
-
calcium chloride
-
5 mM, 36% residual activity
cholesterol
-
1 mM, 57% inhibition
coumarin 7-O-sulfamate
-
-
cysteine
-
10 mM, 15% inhibition
dehydroepiandrosterone
dithiothreitol
-
5 mM, 45% residual activity
estra-1,3,5-(10)-triene-17-one-3-boronic acid
-
competitive
estrone
-
-
estrone 3-O-sulfamate
-
-
Estrone 3-sulfate
estrone-3-O-(N,N-dimethyl)sulfamate
-
-
estrone-3-O-(N-methyl)sulfamate
-
-
estrone-3-O-methylthiophosphonate
-
-
estrone-3-O-sulfamate
estrone-3-sulfamate
glutathione
-
reduced form, 5 mM, 23.5% residual activity
human pituitary luteinizing hormone
-
human pituitary LH, reduces activity to 85% of baseline at 5 ng/ml, dose-dependent
-
interleukin-1beta
-
marked inhibition of mRNA expression and STS activity
-
irosustat
KH2PO4
-
5 mM, 25% inhibition
KW-2581
-
active site-directed irreversible steroidal inhibitor
letrozole
-
-
methyl 2-(1-adamantyl)-4-oxo-4H-chromene-6-carboxylate
-
-
N,N-dihydroxy-6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromene-3-sulfinamide
-
-
N,N-dimethoxy-6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromene-3-sulfinamide
-
-
N-acetylated estrone 3-O-sulfamate
-
inhibits the enzyme irreversibly, albeit much less potently than estrone 3-O-sulfamate
Na2B4O7
-
-
Na2SO3
-
5 mM, 43% inhibition
Na2SO4
-
5 mM, 18% inhibition
p-Nitrophenyl sulfate
-
-
phosphate
-
-
pregnenolone
-
1 mM, 10% inhibition
Steroids
-
overview, e.g. estrone, estradiol, C21 steroids, C19 steroids
STX213
-
phenol sulfamate pharmacophore, irreversible total inhibition from 10-1000 nM in Ishikawa cells, in vivo: upon administration of 1 mg/kg body mass/day reduced tumor growth over 28-day period in transplanted Ishikawa cells in MF-1 nude ovariectomized mice in the presence of estradiol sulfate (prerequisite for tumor cell development in ovariectomized mice), abolished liver STS activity, and reduced plasma estradiol levels
STX64
sulfamic acid 2-bromo-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethyl)phenyl ester
-
ethylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 2-bromo-4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propyl)phenyl ester
-
propylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 2-bromo-4-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]methyl]phenyl ester
-
dual aromatase-sulfatase inhibitor, IC50 value for aromatase 0.82 nM
sulfamic acid 2-chloro-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethyl)phenyl ester
-
ethylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 2-chloro-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethylsulfanyl)phenyl ester
-
thioether linker based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 2-chloro-4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propyl)phenyl ester
-
propylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 3-(((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)methylsulfanyl)phenyl ester
-
thioether linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 3-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethylsulfanyl)phenyl ester
-
thioether linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(((4-cyanophenyl)-(1,2,4)triazol-4-ylamino)methylsulfanyl)phenyl ester
-
thioether linker, , based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold, best STS inhibitor of tested dual inhibitor compounds
sulfamic acid 4-((2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethyl)methylsulfamoyl)phenyl ester
-
N-methylated sulfonamide linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(10-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)decylsulfanyl)phenyl ester
-
thioether linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethyl)phenyl ester
-
ethylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethylsulfanylmethyl)phenyl ester
-
thioether linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethyl)-2-fluorophenyl ester
-
ethylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-propyl)-2-fluorophenyl ester
-
propylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propyl)phenyl ester
-
propylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propylsulfanyl)phenyl ester
-
thioether linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(5-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)pentylsulfanyl)phenyl ester
-
thioether linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 5-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]-methyl]-2-fluorophenyl ester
-
dual aromatase-sulfatase inhibitor, IC50 value for aromatase 0.77 nM
TX-1299
-
non-steroid Theramex compound, strong inhibitor, IC50: 5.3 nM in JEG-3 cells, 0.76 nM in MCF-7 cells
-
TX-1492
-
non-steroid Theramex compound, strong inhibitor, IC50: 22.5 nM in JEG-3 cells, 0.07 nM in MCF-7 cells
-
TX-1506
-
non-steroid Theramex compound, strong inhibitor, IC50: 11.9 nM in JEG-3 cells, 0.06 nM in MCF-7 cells
-
vanadium oxide(V)
-
50 mM, 51% residual activity
Zinc acetate
-
1.25 mM, 53% residual activity
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
17beta estradiol
-
exposure to 17beta estradiol causes 9% increase of estrone 3-sulfate sulfatase activity in mammary myoepithelial cells after 6 days, but 70% reduction in MCF-7 cells
1alpha,25-dihydroxyvitamin D3
-
upregulation of enzyme activity. In HL-60 cell, stimulation is augmented by retinoid X-receptor agonists, blocked by retinoid X-receptor specific antagonists, and retinoic acid receptor specific agonists and antagonist have no effect. In NB-4 cell, upregulation is unaffected by the specific classical nuclear vitamin D receptor and retinoid X-receptor antagonists, but is blocked by a plasma-membrane associated vitamin D receptor antagonist and increases by plasma-membrane associated vitamin D receptor agonists
ascorbic acid
-
activates
Digitonin
-
activates
estrone
-
slightly activates
glutathione
Insulin
-
human recombinant insulin, 30% activation at 10 ng/ml
-
interleukin 6
-
plus tumor necrosis factor alpha, increases STS activity in mock transfected MCF-7 cells and further increases STS activity in transfected MCF-7 cells, activation occurs independently of STS promoter and enhancer elements, may activate via a post-translational modification of STS or by increasing substrate availability
interleukin-1
-
L-beta-phenylalanine
-
5 mM, 169% of initial activity
L-cysteine
-
5 mM, 202% of initial activity
lithocholic acid
-
5 mM, 226% of initial activity
p-chloromercuribenzoate
-
activates
Tumor necrosis factor alpha
-
additional information
-
not activated by 2-mercaptoethanol, cysteine or dithiothreitol
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0043
17beta-estradiol sulfate
pH 7.0, 37°C
0.0057
cholesterol 3-sulfate
pH 7.0, 37°C
0.0029
dehydroepiandrosterone 3-sulfate
pH 7.0, 37°C
0.0051
Estrone 3-sulfate
pH 7.0, 37°C
0.0018
pregnenolone 3-sulfate
pH 7.0, 37°C
0.02
16alpha-hydroxydehydroepiandrosterone 3-sulfate
-
-
0.217
4-methylumbelliferylsulfate
-
-
0.00313
androstenediol 3-sulfate
-
-
0.00526
cholesterol 3-sulfate
-
-
0.0067
Cholesterol sulfate
-
pH 6.4, 37°C
0.014
dehydroandrosterone 3-sulfate
-
-
0.003 - 0.05
dehydroepiandrosterone 3-sulfate
0.0017 - 0.013
dehydroepiandrosterone sulfate
0.005 - 0.0506
esterone 3-sulfate
0.0063 - 0.035
Estrone 3-sulfate
0.00685 - 0.07275
Estrone sulfate
0.1 - 0.58
methylumbelliferyl sulfate
1.32
p-Nitrophenyl sulfate
-
-
1
p-nitrophenylsulfate
-
-
0.00073
pregnenolone 3-sulfate
-
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
6.48
dehydroepiandrosterone sulfate
-
pH 8, 37°C
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0022
(2-(1-adamantyl)-4-oxo-4H-chromen-6-yl)(oxo)acetic acid
-
-
0.05
(2-(1-adamantyl)-4-oxo-4H-chromen-6-yl)acetic acid
-
or above
0.00025
17alpha-benzyl-17beta-hydroxyestra-1,3,5-(10)-triene-3-boronic acid
-
30°C, pH 7.0
0.00025
17alpha-benzyl-3,17beta-dihydroxyestra-1,3,5-(10)-triene
-
30°C, pH 7.0
0.02
2-(1-adamantyl)-4-oxo-4H-chromene-6-carbaldehyde
-
or above
0.05
2-(1-adamantyl)-4-oxo-4H-chromene-6-carboxamide
-
or above
0.0005
2-(1-adamantyl)-4-oxo-4H-chromene-6-carboxylic acid
-
-
0.05
2-(1-adamantyl)-4-oxo-4H-thiochromene-6-carbonitrile
-
or above
0.00053
2-(1-adamantyl)-4-oxo-4H-thiochromene-6-carboxylic acid
-
-
0.032
2-(1-adamantyl)-6-(hydroxymethyl)-4H-chromen-4-one
-
-
0.0032
2-(1-adamantyl)-6-glycoloyl-4H-chromen-4-one
-
-
0.000085
2-formyl-17alpha-benzyl-17beta-hydroxyestra-1,3,5(10)-triene
-
pH 7.0, temperature not specified in the publication
0.0046
2-tert-butyl-6-hydroxy-4H-chromen-4-one
-
30°C, pH 7.0
0.000015
667-coumate
-
37°C
0.0021 - 0.007
estra-1,3,5-(10)-triene-17-one-3-boronic acid
0.063
estrone
-
30°C, pH 7.0
0.000026
KW-2581
-
37°C
0.05
methyl 2-(1-adamantyl)-4-oxo-4H-chromene-6-carboxylate
-
or above
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.004633
(R)-1-[(4-cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
enzyme activity in JEG-3 cells, IC50 for aromatase = 0.0000032 mM
0.000553
(S)-1-[(4-cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
enzyme activity in JEG-3 cells, IC50 for aromatase = 0.0000143 mM
0.0026
1-[(4-cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
enzyme activity in JEG-3 cells, IC50 for aromatase = 0.000003 mM
0.00092
1-[(4-cyanophenyl)(3-chloro-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
enzyme activity in JEG-3 cells, IC50 for aromatase = 0.000012 mM
0.000476
1-[bis-(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
enzyme activity in JEG-3 cells, IC50 for aromatase = 0.000043 mM
0.0000159
2-chloro-4-[5-(2,6-difluoro-3-hydroxybenzoyl)thiophen-2-yl]phenyl sulfamate
Homo sapiens
whole cell assay, pH not specified in the publication, temperature not specified in the publication
0.000000035
3-sulfamoyloxy-N-3,3,3-trifluoropropyl-16,17-seco-estra-1,3,4(10)-triene-16,17-imide
Homo sapiens
in vitro JEG-3 cells: 0.001-10000 nmol/l inhibitor and incubation with estrone-3-sulfate, IC50 for human carbonic anhydrase II = 0.000003 mM
0.00018
3-[4-(3,4-difluoro-benzoylamino)-phenyl]-coumarin-7-O-sulfamate
Homo sapiens
pH 7.4, 37°C
0.0018
3-[4-[2-(2,5-bis-trifluoromethyl-phenyl)-acetylamino]-phenyl]-coumarin-7-O-sulfamate
Homo sapiens
pH 7.4, 37°C
2.5
4-fluoro-17beta-(3'-trifluoromethylbenzene)sulfonamideestra-1,3,5(10)-trien-3-ol
Homo sapiens
pH 7.4, 24°C
1
4-nitro-17beta-4'-biphenylsulfonamide-1,3,5(10)-estratrien-3-ol
Homo sapiens
pH 7.4, 24°C
0.00000018
STX213
Homo sapiens
in vitro JEG-3 cells: 0.001-10000 nmol/l inhibitor and incubation with estrone-3-sulfate, IC50 for human carbonic anhydrase II = 0.000005 mM
0.0000015
STX64
Homo sapiens
enzyme activity in JEG-3 cells, IC50 for aromatase = 0.0003 mM
0.0000163
2',4'-dicyano-N,N-dihydroxybiphenyl-4-sulfinamide
Homo sapiens
-
-
0.000078
2-methoxy-6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.001
2-phenylindole sulfamate
Homo sapiens
-
2-phenylindole sulfamates with lipophilic side chains in 1- or 5-position of the indole with IC50-values between 2 nM and 0.001 mM, irreversibly inhibits hydrolysis of estrone sulfate in MDA-MB 231 cells, inhibits gene activation in estrogen receptor-posi
0.086
2-t-butyl-4H-1-benzopyran-4-one-6-boronic acid
Homo sapiens
-
30°C, pH 7.0
0.0000326
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-4'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.006333
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-5'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.00016
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chlorobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.00014
3'-((1H-1,2,4-triazol-1-yl)methyl)-4'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.0055
3'-((1H-1,2,4-triazol-1-yl)methyl)biphenyl-4-yl sulfamate
Homo sapiens
-
-
0.032
3-benzyl-4-methylcoumarin-7-O-sulfamate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.008
3-hexyl-4-methylcoumarin-7-O-sulfamate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000032
3-oxo-1,3-dihydro-2H-cyclobuta[c]chromen-6-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.0000286
4'-((1H-1,2,4-triazol-1-yl)methyl)-2'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.00005
4'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-2'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.00038
4-(((4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino)methyl)-2-methoxyphenyl sulfamate
Homo sapiens
-
-
0.00004
4-fluoro-17alpha-benzyl-17beta-hydroxyestra-1,3,5(10)-triene
Homo sapiens
-
pH 7.0, temperature not specified in the publication
0.000007
4-oxo-1,2,3,4-tetrahydrocyclopenta[c]chromen-7-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.000035
5'-((1H-1,2,4-triazol-1-yl)methyl)-2'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.0000055
5'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-2'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.01
5-(((4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino)methyl)-2-methoxyphenyl sulfamate
Homo sapiens
-
-
0.0024
5-methyl-6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sulfamate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0016
6-oxo-6,7,8,9,10,11,12,13,14,15,16,17,18,19-tetradecahydrocyclopentadeca[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.00022
6-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclotrideca[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.000000015
6-oxo-6,7,8,9,10,11,12,13,14,15-decahydrocycloundeca[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.000000022
6-oxo-6,7,8,9,10,11,12,13-octahydrocyclonona[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.00024
6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sulfamate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.001
6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-ylsulfamide
Homo sapiens
-
above, pH not specified in the publication, temperature not specified in the publication
0.000283
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-2-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.01
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl dimethylsulfamate
Homo sapiens
-
above, in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.0000015
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.0001
6-oxo-7,8,9,10,11,12,13,14,15,16-decahydro-6H-cyclododeca[c]-chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.000000025
6-oxo-7,8,9,10,11,12,13,14-octahydro-6H-cyclodeca[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.0000009
6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.00000043 - 0.0000051
6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulfamate
0.171
6-oxo-8,9,10,11-tetrahydro-7H-cylohepta-[c][1]benzopyran-boronic acid
Homo sapiens
-
30°C, pH 7.0
0.0000029
667-coumate
Homo sapiens
-
37°C
0.00000008 - 0.0000032
estrone-3-sulfamate
0.000015
KW-2581
Homo sapiens
-
37°C
0.0000015
N,N-dihydroxy-6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromene-3-sulfinamide
Homo sapiens
-
-
0.0000015 - 0.000008
STX64
0.0061
sulfamic acid 2-bromo-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.000001 mM
0.0055
sulfamic acid 2-bromo-4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000015 mM
0.000039
sulfamic acid 2-bromo-4-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]methyl]phenyl ester
Homo sapiens
-
-
0.0015
sulfamic acid 2-chloro-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000017 mM
0.0012
sulfamic acid 2-chloro-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethylsulfanyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.00000045 mM
0.0015
sulfamic acid 2-chloro-4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000021 mM
0.0035
sulfamic acid 3-(((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)methylsulfanyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000039 mM
0.01
sulfamic acid 3-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethylsulfanyl)phenyl ester
Homo sapiens
-
larger than 0.01 mM, inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000017 mM
0.0009
sulfamic acid 4-(((4-cyanophenyl)-(1,2,4)triazol-4-ylamino)methylsulfanyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000055 mM, best STS inhibitor of tested dual inhibitors
0.01
sulfamic acid 4-((2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethyl)methylsulfamoyl)phenyl ester
Homo sapiens
-
larger than 0.01 mM, inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.00001 mM
0.0019
sulfamic acid 4-(10-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)decylsulfanyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000055 mM
0.01
sulfamic acid 4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethyl)phenyl ester
Homo sapiens
-
larger than 0.01 mM, inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000021 mM
0.01
sulfamic acid 4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethylsulfanylmethyl)phenyl ester
Homo sapiens
-
larger than 0.01 mM, inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.00000037 mM
0.0026
sulfamic acid 4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethyl)-2-fluorophenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.000002 mM
0.0016
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-propyl)-2-fluorophenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000025 mM
0.01
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propyl)phenyl ester
Homo sapiens
-
larger than 0.01 mM, inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.00000089 mM
0.01
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propylsulfanyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 larger than 0.01 mM, IC50 for aromatase = 0.00000051 mM
0.001
sulfamic acid 4-(5-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)pentylsulfanyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.00000073 mM
0.00059
sulfamic acid 5-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]-methyl]-2-fluorophenyl ester
Homo sapiens
-
-
0.00000076 - 0.0000053
TX-1299
-
0.0000225
TX-1492
Homo sapiens
-
non-steroid Theramex compound, strong inhibitor, IC50: 22.5 nM in JEG-3 cells
-
0.00000006 - 0.0000119
TX-1506
-
additional information
1-[(4-cyanophenyl)(4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.0000128
-
pH 7.5, 37°C, subcortical white matter
0.000015
-
in primary mammary carcinoma
0.0000265
-
pH 7.5, 37°C, cerebral neocortex
0.385
-
pH 6.4, 37°C
1.52
-
-
1.556
-
pH 8, 37°C, hydrolysis of dehydroepiandrosterone sulfate
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5 - 5.5
6.9
-
f-form
7 - 7.2
-
-
7 - 7.5
-
STS from temporal lobe
7.3
-
p-nitrophenyl sulfate
7.3 - 7.5
7.5 - 8
-
placenta
7.7
-
fast form
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
pI VALUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.1
-
isoelectric focussing, pH-gradient 2-10
8.7
-
isoelectric focusing
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
transcription is regulated by two promoters which differ from the prevalent placental one. Specific activity of adipose tissue enzyme is about 50-100 times lower than by placenta enzyme
Manually annotated by BRENDA team
moderate level of enzyme immunoreactivity
Manually annotated by BRENDA team
endometrial stromal fibroblast
Manually annotated by BRENDA team
human embryonic kidney carcinoma cell line selected for overexpression of transfected His6-tagged STS cDNA to aid purification of the His6-tagged STS protein and subsequent antibody production in mice and rabbits
Manually annotated by BRENDA team
strong positive immunostaining for enzyme
Manually annotated by BRENDA team
strong positive immunostaining for enzyme
Manually annotated by BRENDA team
strong positive immunostaining for enzyme
Manually annotated by BRENDA team
-
adult, relatively high STS activity
Manually annotated by BRENDA team
-
analysis of enzyme activity and sulfuryl trasnferase activity in the 55 most frequent human brain tumors
Manually annotated by BRENDA team
-
endometrial tumor, evaluation of aromatase and steryl-sulfatase activites using tritium-labeled steroids
Manually annotated by BRENDA team
-
from 10 patients in follicular and early luteal phases during gynecological laparotomy, epithelium, expression pattern
Manually annotated by BRENDA team
-
from normal and malignant breast tissue, study of the regulation of STS mRNA expression, expression in fibroblasts derived from breast tissue proximal to tumors, breast tumor tissue and reduction mammoplasty tissue, effect of menopausal status
Manually annotated by BRENDA team
-
luteinized, follicle
Manually annotated by BRENDA team
-
scalp biopsies, beard and occipital hair follicles ex vivo, predominantly expressed in the dermal papilla
Manually annotated by BRENDA team
-
human embryonic kidney carcinoma cell line
Manually annotated by BRENDA team
-
acute myeloid leukaemia cell line
Manually annotated by BRENDA team
-
human prostate cancer cells with mutated androgen receptor, as is typical for many human prostate tumors
Manually annotated by BRENDA team
-
adult
Manually annotated by BRENDA team
-
peripheral blood lymphocyte
Manually annotated by BRENDA team
-
from normal mammary tissue, slightly lower STS mRNA expression but 120times higher STS activity than in MCF-7 cells
Manually annotated by BRENDA team
-
stably transfected breast cancer cells
Manually annotated by BRENDA team
-
the MCS-2 cell line is established by introduction of the human STS gene into estrogen-dependent human breast cancer MCF-7 cells, MCS-2 cells are transplanted into female nude mice
Manually annotated by BRENDA team
-
mammary carcinoma cell line
Manually annotated by BRENDA team
-
primary myoepithelial cell, highest activity of steryl sulfatase and aryl sulfatase B of all the cell lines tested
Manually annotated by BRENDA team
-
acute myeloid leukaemia cell line
Manually annotated by BRENDA team
-
adult
Manually annotated by BRENDA team
-
luteinized granulosa cells
Manually annotated by BRENDA team
-
human ovarian cancer cell line
Manually annotated by BRENDA team
-
gene expression of both sulfotransferase and steroid sulfatase in all prostate cancer cell lines examined, accompanied by synthesis of estrone and estradiol. 85% of cell lines show immunoreactivity for steroid sulfatase
Manually annotated by BRENDA team
-
remarkably low activity of arylsulfatase A, arylsulfatase B, galacose 6-sulfatase and steryl sulfatase, but not iduronate 2-sulfatase
Manually annotated by BRENDA team
-
human female vascular smooth muscle cell line
Manually annotated by BRENDA team
-
1-3.7% of the mRNA levels of placenta, adult
Manually annotated by BRENDA team
-
STS expression levels are higher in the vascular smooth muscle cells obtained from female aortas with mild atherosclerotic changes than in those with severe atherosclerotic changes in male aortas regardless of atherosclerotic changes
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
membrane-bound
Manually annotated by BRENDA team
additional information
-
subcellular distribution of STS in the temporal lobe
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
both expression and activity of STS increase in response to a decidualisation stimulus. Inhibition of STS activity disrupts bioavailability of estrogens and inhibits decidualisation responses consistent with stromal utilisation of sulfated steroids as precursors to active hormones during decidualisation
malfunction
metabolism
physiological function
additional information
-
active site residues are D35, D36, FGS75, R79, K134, H136, H290, D342, Q343, and K368
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION?
STS_HUMAN
583
2
65492
Swiss-Prot
Secretory Pathway (Reliability: 1)
PDB
SCOP
CATH
UNIPROT
ORGANISM
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
61000
SDS-PAGE, immunoblot analysis with specific antibody
64000
x * 64000, SDS-PAGE of enzymes from placenta and adipose tissue
65000
x * 65000, SDS-PAGE
103000 - 105000
-
brain
183000
-
placenta, s-form, gel filtration, two isoforms s- and f-form
200000
-
liver, f-form, gel filtration, two isoforms s- and f-form
238000
-
gel filtration
250000
-
gel filtration
270000
30000
-
x * 30000, SDS-PAGE
390000
-
placenta, gel filtration
440000
-
placenta
500000 - 600000
-
placenta, gel filtration
54000
-
amino acid analysis
62000
64000
-
placenta, reduced, SDS-PAGE
65000
-
x * 65000, SDS-PAGE
73000
-
placenta, SDS-PAGE
74000
-
gel filtration
78000
additional information
-
native PAGE analysis of solubilized single crystals of ES shows all possible oligomeric states between a monomer and a tetramer, but predominantly the monomeric and dimeric states
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
dimer
-
coprecipitation of mutant enzyme with FLAG-tagged enzyme
hexamer
-
-
monomer
-
1 * 78000, solubilized in Triton X-100
trimer
-
alpha, 3 * 78000, SDS-PAGE,solubilized in Triton X-100
additional information
-
all oligomeric states between a monomer and a tetramer are possible, varying aggregation properties of enzyme under various buffer, pH, detergent and ionic strength conditions, gel filtration suggests ES to be predominantly a homotetramer, native PAGE analysis of solubilized single crystals of ES shows all possible oligomeric states between a monomer and a tetramer, but predominantly the monomeric and dimeric states
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
glycoprotein
4 potential glycosylation sites
proteolytic modification
enzyme expression is driven by six different promoters giving rise to transcripts with unique first exons. Whatever ATG is actually used, the differences on protein level are restricted to the signal peptide which is post-transcriptionally cleaved
glycoprotein
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
molecular docking of inhibitors 3-[4-(3,4-difluoro-benzoylamino)-phenyl]-coumarin-7-O-sulfamate, 3-[4-[2-(2,5-bis-trifluoromethyl-phenyl)-acetylamino]-phenyl]-coumarin-7-O-sulfamate. Predicted free docking energies are in the range of -7.6 to -9.5 kcal/mol
crystal structure analysis of placenta microsome enzyme, overview
-
full-length, active enzyme form, X-ray analysis
-
in complex with inhibitor sulfamic acid 2-bromo-4-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]methyl]phenyl ester
-
molecular docking of inhibitors 3-hexyl-4-methylcoumarin-7-O-sulfamate and 3-benzyl-4-methylcoumarin-7-O-sulfamate into the active site of steryl sulfatase
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
DELTA1-21
lacks 21 N-terminal amino acids, that encode the signal peptide, reduced STS activity
DELTA185-583
lacks 399 C-terminal amino acids, reduced STS activity
H136F
point mutation in histidine 136, reduced STS activitiy
H136W
point mutation in histidine 136, reduced STS activity
H136Y
point mutation in histidine 136, reduced STS activity
N259Q
point mutation in asparagine 259 glycosylation site, reduced STS activity
N333Q
point mutation in other potential glycosylation site asparagine 333, no reduced STS activity
N459Q
point mutation in other potential glycosylation site asparagine 459, no reduced STS activity
N47Q
point mutation in asparagine 47 glycosylation site, reduced STS activity
N47Q/N259Q
double mutation in asparagine 47 and 259 glycosylation sites, reduced STS activity
N54Q
point mutation in in asparagine 54 non-glycosylation site , no reduced STS activity
P212G
point mutation in proline 212, no reduced STS activity
C446Y
-
patient with X-linked ichthyosis
H444R
-
patient with X-linked ichthyosis
Q560P
-
no effect of mutation on enzyme synthesis and degradation, dominant negative effect on enzyme activity when coexisting with wild-type enzyme
R419S
-
patient with X-linked ichthyosis
S341L
-
patient with X-linked ichthyosis
W372P
-
patient with X-linked ichthyosis
W372R
-
patient with X-linked ichthyosis
additional information
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
100
-
5 min, 87% residual activity
37
-
5 h, 20% loss of activity
57
-
s-form: 50% loss of activity
80
-
5 min, 100% residual activity
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
room temperature, crystalline state of enzyme, more than 30 days, less than 33% loss of specific activity
-
room temperature, n-octyl-beta-D-glucopyranoside, several weeks, nearly stable
-
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
affinity chromatography with NiCl2-primed HisTrap Chelating columns and concentrated 6-fold using ICON concentrators
enzyme does not copurify with oestrone sulfate sulfohydrolase
-
of the recombinant protein
-
solubilized with 0.5% Triton X-100, two fractions with cholesterol sulfate sulfohydrolase activity are separated by DEAE-cellulose chromatography, purification of the 30 kDa enzyme
-
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expression in COS-7 cell
His6-tagged wild-type STS cDNA subcloned into pCEP4, transfected into 293-EBNA cells, cell line with stable overexpression of STS-His6 selected for production of tagged wildtype STS, subsequent specific antibody production, mutated STS is transfected into human MCF-7 cells and monkey COS-1 cells to test for STS activity by immunoblotting
2.4 kb STS cDNA, expression in MCF-7 and COS-1 cells
-
expression in Escherichia coli and CHO cells
-
expression in monkey kidney COS-1 cells
-
expression in mouse A9 cells
-
overexpression of STS gene in human breast cancer MCF-7 cells, i.e. MCS-2 cells, transplanted in female nude mice
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
expression increases upon stimulation with decidualisation media
STS activity and gene expression are decreased during differentiation in cells treated with osteogenic supplement containing dexamethasone. The NFkappaB activators lipopolysaccharide and phorbol myristate acetate increase STS expression in undifferentiated and differentiated MG-63 cells, while the NFkappaB inhibitor BAY-11-7082 partially blocks these responses
shikonin, an ingredient of Lithospermum erythrorhizon, down-regulates the expression and activity of steroid sulfatase in breast cancer cells
-
Shu-Gan-Liang-Xue decoction down-regulates the expression of steroid sulfatase genes in human breast carcinoma MCF-7 cells in a dose-dependent manner
-
steroid sulfatase expression is upregulated in breast carcinomas
-
trichostatin A treatment suppresses STS mRNA expression
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
analysis
-
method for the evaluation of aromatase and steryl-sulfatase activites in endometrial tumors using tritium-labeled steroids
medicine
pharmacology
additional information
-
gene expression of both sulfotransferase and steroid sulfatase in all prostate cancer cell lines examined, accompanied by synthesis of estrone and estradiol. 85% of cell lines show immunoreactivity for steroid sulfatase
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Daniel, W.L.
Arylsulfatase C and the streroid sulfatases
Isozymes Curr. Top. Biol. Med. Res.
12
189-228
1985
Aspergillus nidulans, Bos taurus, Chlamydomonas reinhardtii, Homo sapiens, Mus musculus, Pseudomonas aeruginosa, Rattus norvegicus
Manually annotated by BRENDA team
Burns, G.R.J.
Purification and partial characterization of arylsulphatase C from human placental microsomes
Biochim. Biophys. Acta
759
199-204
1983
Homo sapiens
Manually annotated by BRENDA team
Noel, H.; Plante, L.; Bleau, G.; Chapdelaine, A.; Roberts, K.D.
Human placental steroid sulfatase: purification and properties
J. Steroid Biochem.
19
1591-1598
1983
Homo sapiens
Manually annotated by BRENDA team
Simard, J.P.S.; Ameen, M.; Chang, P.L.
Biochemical characterization of arylsulfatase-C isozymes in human fibroblasts
Biochem. Biophys. Res. Commun.
128
1388-1394
1985
Homo sapiens
Manually annotated by BRENDA team
Conary, J.; Nauerth, A.; Burns, G.; Hasilik, A.; von Figura, K.
Steroid sulfatase. Biosynthesis and processing in normal and mutant fibroblasts
Eur. J. Biochem.
158
71-76
1986
Homo sapiens
Manually annotated by BRENDA team
Dibbelt, L.; Kuss, E.
Human placental steryl-sulfatase. Enzyme purification, production of antisera, and immunoblotting reactions with normal and sulfatase-deficient placentas
Biol. Chem. Hoppe-Seyler
367
1223-1229
1986
Homo sapiens
Manually annotated by BRENDA team
Dibbelt, L.; Kuss, E.
Human placental steroid-sulfatase. Kinetics of the in-vitro hydrolysis of dehydroepiandrosterone 3-sulfate and of 16 alpha-hydroxydehydroepiandrosterone 3-sulfate
Hoppe-Seyler's Z. Physiol. Chem.
364
187-191
1983
Homo sapiens
Manually annotated by BRENDA team
Vaccaro, A.M.; Salvioli, R.; Muscillo, M.; Renola, L.
Purification and properties of arylsulfatase C from human placenta
Enzyme
37
115-126
1987
Homo sapiens
Manually annotated by BRENDA team
Yen, P.H.; Allen, E.; Marsh, B.; Mohandas, T.; Wang, N.; Taggart, R.T.; Shapiro, L.J.
Cloning and expression of steroid sulfatase cDNA and the frequent occurrence of deletions in STS deficiency: implications for X-Y interchange
Cell
49
443-454
1987
Homo sapiens
Manually annotated by BRENDA team
Bonifas, J.M.; Morley, B.J.; Oakey, R.E.; Kan, Y.W.Epstein E.H.
Cloning of a cDNA for steroid sulfatase: frequent occurrence of gene deletions in patients with recessive X chromosome-linked ichthyosis
Proc. Natl. Acad. Sci. USA
84
9248-9251
1987
Homo sapiens
Manually annotated by BRENDA team
Dibbelt, L.; Kuss, E.
Human placental steroid-sulfatase solubilized with a cholic-acid derivative: molecular mass, kinetic properties and susceptibility to glycosidases [retracted by Dibbelt L, Kuss E. In: Biol Chem Hoppe Seyler 1991 Mar;372(3):186]
Hoppe-Seyler's Z. Physiol. Chem.
365
1145-1153
1984
Homo sapiens
Manually annotated by BRENDA team
Tseng, L.; Mazella, J.; Lee, L.Y.; Stone, M.L.
Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma
J. Steroid Biochem.
19
1413-1417
1983
Homo sapiens
Manually annotated by BRENDA team
Payne, A.H.
Gonadal steroid sulfates and sulfatase. V. Human testicular steroid sulfatase: partial characterization and possible regulation by free steroids
Biochim. Biophys. Acta
258
473-483
1972
Homo sapiens
Manually annotated by BRENDA team
Shankaran, R.; Ameen, M.; Daniel, W.L.; Davidson, R.G.; Chang, P.L.
Characterization of arylsulfatase C isozymes from human liver and placenta
Biochim. Biophys. Acta
1078
251-257
1991
Homo sapiens
Manually annotated by BRENDA team
Suzuki, T.; Hirato, K.; Yanaihara, T.; Kadofuku, T.; Sato, T.; Hoshino, M.; Yanaihara, N.
Purification and properties of steroid sulfatase from human placenta
Endocrinol. Jpn.
39
93-101
1992
Homo sapiens
Manually annotated by BRENDA team
Haning, R.V., Jr.; Hackett, R.J.; Canick, J.A.
Steroid sulfatase in the human ovary and placenta: enzyme kinetics and phosphate inhibition
J. Steroid Biochem. Mol. Biol.
41
161-165
1992
Homo sapiens
Manually annotated by BRENDA team
Purohit, A.; Reed, M.J.; Morris, N.C.; Williams, G.J.; Potter, B.V.
Regulation and inhibition of steroid sulfatase activity in breast cancer
Ann. N. Y. Acad. Sci.
784
40-49
1996
Homo sapiens
Manually annotated by BRENDA team
Alperin, E.S.; Shapiro, L.J.
Characterization of point mutations in patients with X-linked ichthyosis. Effects on the structure and function of the steroid sulfatase protein
J. Biol. Chem.
272
20756-20763
1997
Homo sapiens
Manually annotated by BRENDA team
Purohit, A.; Potter, B.V.; Parker, M.G.; Reed, M.J.
Steroid sulphatase: expression, isolation and inhibition for active-site identification studies
Chem. Biol. Interact.
109
183-193
1998
Helix pomatia, Homo sapiens
Manually annotated by BRENDA team
Woo, L.W.; Howarth, N.M.; Purohit, A.; Hejaz, H.A.; Reed, M.J.; Potter, B.V.
Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase
J. Med. Chem.
41
1068-1083
1998
Homo sapiens
Manually annotated by BRENDA team
Slavakis, A.P.; Oakey, R.E.
Aromatase activity of steroid sulphatase-deficient placentae
J. Steroid Biochem.
19
1599-1603
1983
Homo sapiens
Manually annotated by BRENDA team
Van der Loos, C.M.; van Breda, A.J.; van den Berg, F.M.; Jobsis, A.C.
The nature of placental steroid sulphatase deficiency in man
J. Steroid Biochem.
19
1743-1746
1983
Homo sapiens
Manually annotated by BRENDA team
Nakamura, Y.; Miki, Y.; Suzuki, T.; Nakata, T.; Darnel, A.D.; Moriya, T.; Tazawa, C.; Saito, H.; Ishibashi, T.; Takahashi, S.; Yamada, S.; Sasano, H.
Steroid sulfatase and estrogen sulfotransferase in the atherosclerotic human aorta
Am. J. Pathol.
163
1329-1339
2003
Homo sapiens
Manually annotated by BRENDA team
Miki, Y.; Nakata, T.; Suzuki, T.; Darnel, A.D.; Moriya, T.; Kaneko, C.; Hidaka, K.; Shiotsu, Y.; Kusaka, H.; Sasano, H.
Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues
J. Clin. Endocrinol. Metab.
87
5760-5768
2002
Homo sapiens
Manually annotated by BRENDA team
Sugawara, T.; Fujimoto, S.
The potential function of steroid sulphatase activity in steroid production and steroidogenic acute regulatory protein expression
Biochem. J.
380
153-160
2004
Homo sapiens
Manually annotated by BRENDA team
Bonser, J.; Walker, J.; Purohit, A.; Reed, M.J.; Potter, B.V.L.; Willis, D.S.; Franks, S.; Mason, H.D.
Human granulosa cells are a site of sulphatase activity and are able to utilize dehydroepiandrosterone sulphate as a precursor for oestradiol production
J. Endocrinol.
167
465-471
2000
Homo sapiens
Manually annotated by BRENDA team
Hoffmann, R.; Rot, A.; Niiyama, S.; Billich, A.
Steroid sulfatase in the human hair follicle concentrates in the dermal papilla
J. Invest. Dermatol.
117
1342-1348
2001
Homo sapiens
Manually annotated by BRENDA team
Steckelbroeck, S.; Nassen, A.; Ugele, B.; Ludwig, M.; Watzka, M.; Reissinger, A.; Clusmann, H.; Ltjohann, D.; Siekmann, L.; Klingmller, D.; Hans, V.H.
Steroid sulfatase (STS) expression in the human temporal lobe: enzyme activity, mRNA expression and immunohistochemistry study
J. Neurochem.
89
403-417
2004
Homo sapiens
Manually annotated by BRENDA team
Newman, S.P.; Purohit, A.; Ghilchik, M.W.; Potter, B.V.L.; Reed, M.J.
Regulation of steroid sulphatase expression and activity in breast cancer
J. Steroid Biochem. Mol. Biol.
75
259-264
2000
Homo sapiens
Manually annotated by BRENDA team
Hernandez-Guzman, F.G.; Higashiyama, T.; Osawa, Y.; Ghosh, D.
Purification, characterization and crystallization of human placental estrone/dehydroepiandrosterone sulfatase, a membrane-bound enzyme of the endoplasmic reticulum
J. Steroid Biochem. Mol. Biol.
78
441-450
2001
Homo sapiens
Manually annotated by BRENDA team
Norkowska, M.; Gniot-Szulzycka, J.
Sterolsulphate sulphohydrolase from human placenta microsomes--30 kDa molecular weight form of cholesterol sulphate sulphohydrolase
J. Steroid Biochem. Mol. Biol.
81
263-271
2002
Homo sapiens
Manually annotated by BRENDA team
Tobacman, J.K.; Hinkhouse, M.; Khalkhali-Ellis, Z.
Steroid sulfatase activity and expression in mammary myoepithelial cells
J. Steroid Biochem. Mol. Biol.
81
65-68
2002
Homo sapiens
Manually annotated by BRENDA team
Shields-Botella, J.; Bonnet, P.; Duc, I.; Duranti, E.; Meschi, S.; Cardinali, S.; Prouheze, P.; Chaigneau, A.M.; Duranti, V.; Gribaudo, S.; Riviere, A.; Mengual, L.; Carniato, D.; Cecchet, L.; Lafay, J.; Rondot, B.; Sandri, J.; Pascal, J.C.; Delansorne, R.
In vitro and in vivo models for the evaluation of new inhibitors of human steroid sulfatase, devoid of residual estrogenic activity
J. Steroid Biochem. Mol. Biol.
84
327-335
2003
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Nakata, T.; Takashima, S.; Shiotsu, Y.; Murakata, C.; Ishida, H.; Akinaga, S.; Li, P.K.; Sasano, H.; Suzuki, T.; Saeki, T.
Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients
J. Steroid Biochem. Mol. Biol.
86
455-460
2003
Homo sapiens
Manually annotated by BRENDA team
Walter, G.; Liebl, R.; von Angerer, E.
2-Phenylindole sulfamates: inhibitors of steroid sulfatase with antiproliferative activity in MCF-7 breast cancer cells
J. Steroid Biochem. Mol. Biol.
88
409-420
2004
Homo sapiens
Manually annotated by BRENDA team
Yanaihara, A.; Yanaihara, T.; Toma, Y.; Shimizu, Y.; Saito, H.; Okai, T.; Higashiyama, T.; Osawa, Y.
Localization and expression of steroid sulfatase in human fallopian tubes
Steroids
66
87-91
2001
Homo sapiens
Manually annotated by BRENDA team
Utsunomiya, H.; Ito, K.; Suzuki, T.; Kitamura, T.; Kaneko, C.; Nakata, T.; Niikura, H.; Okamura, K.; Yaegashi, N.; Sasano, H.
Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma
Clin. Cancer Res.
10
5850-5856
2004
Homo sapiens
Manually annotated by BRENDA team
Yanaihara, A.; Otsuka, Y.; Iwasaki, S.; Okai, T.; Yanaihara, T.
Strong expression of steroid sulfatase in human cumulus cells in patients with endometriosis
Fertil. Steril.
84
464-467
2005
Homo sapiens
Manually annotated by BRENDA team
Hughes, P.J.; Steinmeyer, A.; Chandraratna, R.A.; Brown, G.
1alpha,25-dihydroxyvitamin D3 stimulates steroid sulphatase activity in HL60 by and NB4 acute myeloid leukaemia cell lines different receptor-mediated mechanisms
J. Cell. Biochem.
94
1175-1189
2005
Homo sapiens
Manually annotated by BRENDA team
Sugawara, T.; Nomura, E.; Hoshi, N.
Both N-terminal and C-terminal regions of steroid sulfatase are important for enzyme activity
J. Endocrinol.
188
365-374
2006
Homo sapiens
Manually annotated by BRENDA team
Horvath, A.; Nussbaumer, P.; Wolff, B.; Billich, A.
2-(1-adamantyl)-4-(thio)chromenone-6-carboxylic acids: potent reversible inhibitors of human steroid sulfatase
J. Med. Chem.
47
4268-4276
2004
Homo sapiens
Manually annotated by BRENDA team
Bhattacharyya, S.; Tobacman, J.K.
Steroid sulfatase, arylsulfatases A and B, galactose-6-sulfatase, and iduronate sulfatase in mammary cells and effects of sulfated and non-sulfated estrogens on sulfatase activity
J. Steroid Biochem. Mol. Biol.
103
20-34
2007
Homo sapiens
Manually annotated by BRENDA team
Nakamura, Y.; Suzuki, T.; Fukuda, T.; Ito, A.; Endo, M.; Moriya, T.; Arai, Y.; Sasano, H.
Steroid sulfatase and estrogen sulfotransferase in human prostate cancer
Prostate
66
1005-1012
2006
Homo sapiens
Manually annotated by BRENDA team
Ahmed, V.; Liu, Y.; Silvestro, C.; Taylor, S.D.
Boronic acids as inhibitors of steroid sulfatase
Bioorg. Med. Chem.
14
8564-8573
2006
Homo sapiens
Manually annotated by BRENDA team
Bochkareva, N.V.; Kondakova, I.V.; Kolomiets, L.A.; Muntyan, A.B.; Shevchenko, V.P.; Nagaev, I.Y.; Shevchenko, K.V.; Myasoedov, N.F.; Dorofeeva, N.N.
Synthesis of highly tritium labeled steroids for evaluation of aromatase and steroidsulfatase activities in endometrial tumors
Bull. Exp. Biol. Med.
142
478-480
2006
Homo sapiens
Manually annotated by BRENDA team
Valle, L.D.; Toffolo, V.; Nardi, A.; Fiore, C.; Bernante, P.; Di Liddo, R.; Parnigotto, P.P.; Colombo, L.
Tissue-specific transcriptional initiation and activity of steroid sulfatase complementing dehydroepiandrosterone sulfate uptake and intracrine steroid activations in human adipose tissue
J. Endocrinol.
190
129-139
2006
Homo sapiens (P08842), Homo sapiens
Manually annotated by BRENDA team
Woo, L.W.; Bubert, C.; Sutcliffe, O.B.; Smith, A.; Chander, S.K.; Mahon, M.F.; Purohit, A.; Reed, M.J.; Potter, B.V.
Dual aromatase-steroid sulfatase inhibitors
J. Med. Chem.
50
3540-3560
2007
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Selcer, K.W.; Difrancesca, H.M.; Chandra, A.B.; Li, P.K.
Immunohistochemical analysis of steroid sulfatase in human tissues
J. Steroid Biochem. Mol. Biol.
105
115-123
2007
Homo sapiens (P08842), Homo sapiens
Manually annotated by BRENDA team
Zaichuk, T.; Ivancic, D.; Scholtens, D.; Schiller, C.; Khan, S.A.
Tissue-specific transcripts of human steroid sulfatase are under control of estrogen signaling pathways in breast carcinoma
J. Steroid Biochem. Mol. Biol.
105
76-84
2007
Homo sapiens
Manually annotated by BRENDA team
Falany, J.L.; Falany, C.N.
Interactions of the human cytosolic sulfotransferases and steroid sulfatase in the metabolism of tibolone and raloxifene
J. Steroid Biochem. Mol. Biol.
107
202-210
2007
Homo sapiens
Manually annotated by BRENDA team
Dalla Valle, L.; Toffolo, V.; Nardi, A.; Fiore, C.; Armanini, D.; Belvedere, P.; Colombo, L.
The expression of the human steroid sulfatase-encoding gene is driven by alternative first exons
J. Steroid Biochem. Mol. Biol.
107
22-29
2007
Homo sapiens (P08842), Homo sapiens
Manually annotated by BRENDA team
Ishida, H.; Sato, N.; Hosogi, J.; Tanaka, H.; Kuwabara, T.
Inactivation of recombinant human steroid sulfatase by KW-2581
J. Steroid Biochem. Mol. Biol.
108
17-22
2008
Homo sapiens
Manually annotated by BRENDA team
Kriz L.; Bicikova, M.; Mohapl, M.; Hill, M.; Cerny, I.; Hampl, R.
Steroid sulfatase and sulfuryl transferase activities in human brain tumors
J. Steroid Biochem. Mol. Biol.
109
31-39
2007
Homo sapiens
Manually annotated by BRENDA team
Niewiadomska, I.; Gniot-Szulzycka, J.
Dehydroepiandrosterone sulphate sulphohydrolase from human placenta microsomes - properties of the purified enzyme
J. Steroid Biochem. Mol. Biol.
99
67-75
2006
Homo sapiens
Manually annotated by BRENDA team
Stanway, S.J.; Delavault, P.; Purohit, A.; Woo, L.W.; Thurieau, C.; Potter, B.V.; Reed, M.J.
Steroid sulfatase: a new target for the endocrine therapy of breast cancer
Oncologist
12
370-374
2007
Homo sapiens
Manually annotated by BRENDA team
Day, J.M.; Purohit, A.; Tutill, H.J.; Foster, P.A.; Woo, L.W.; Potter, B.V.; Reed, M.J.
The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy
Ann. N. Y. Acad. Sci.
1155
80-87
2009
Homo sapiens
Manually annotated by BRENDA team
Fournier, D.; Poirier, D.
Estradiol dimers as a new class of steroid sulfatase reversible inhibitors
Bioorg. Med. Chem. Lett.
19
693-696
2009
Homo sapiens
Manually annotated by BRENDA team
Sato, R.; Suzuki, T.; Katayose, Y.; Miura, K.; Shiiba, K.; Tateno, H.; Miki, Y.; Akahira, J.; Kamogawa, Y.; Nagasaki, S.; Yamamoto, K.; Ii, T.; Egawa, S.; Evans, D.B.; Unno, M.; Sasano, H.
Steroid sulfatase and estrogen sulfotransferase in colon carcinoma: regulators of intratumoral estrogen concentrations and potent prognostic factors
Cancer Res.
69
914-922
2009
Homo sapiens
Manually annotated by BRENDA team
Bubert, C.; Woo, L.W.; Sutcliffe, O.B.; Mahon, M.F.; Chander, S.K.; Purohit, A.; Reed, M.J.; Potter, B.V.
Synthesis of aromatase inhibitors and dual aromatase steroid sulfatase inhibitors by linking an arylsulfamate motif to 4-(4H-1,2,4-triazol-4-ylamino)benzonitrile: SAR, crystal structures, in vitro and in vivo activities
ChemMedChem
3
1708-1730
2008
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Foster, P.A.; Woo, L.W.; Potter, B.V.; Reed, M.J.; Purohit, A.
The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer
Endocrinology
149
4035-4042
2008
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Wood, P.M.; Woo, L.W.; Labrosse, J.R.; Trusselle, M.N.; Abbate, S.; Longhi, G.; Castiglioni, E.; Lebon, F.; Purohit, A.; Reed, M.J.; Potter, B.V.
Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity
J. Med. Chem.
51
4226-4238
2008
Homo sapiens (P08842)
Manually annotated by BRENDA team
Woo, L.W.; Fischer, D.S.; Sharland, C.M.; Trusselle, M.; Foster, P.A.; Chander, S.K.; Di Fiore, A.; Supuran, C.T.; De Simone, G.; Purohit, A.; Reed, M.J.; Potter, B.V.
Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography
Mol. Cancer Ther.
7
2435-2444
2008
Rattus norvegicus, Homo sapiens (P08842), Homo sapiens
Manually annotated by BRENDA team
Stengel, C.; Newman, S.P.; Day, J.M.; Tutill, H.J.; Reed, M.J.; Purohit, A.
Effects of mutations and glycosylations on STS activity: a site-directed mutagenesis study
Mol. Cell. Endocrinol.
283
76-82
2008
Homo sapiens (P08842), Homo sapiens
Manually annotated by BRENDA team
Fu, J.; Weise, A.M.; Falany, J.L.; Falany, C.N.; Thibodeau, B.J.; Miller, F.R.; Kocarek, T.A.; Runge-Morris, M.
Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression
Breast Cancer Res. Treat.
120
35-45
2010
Homo sapiens
Manually annotated by BRENDA team
Zhang, Y.; Qian, R.Q.; Li, P.P.
Shikonin, an ingredient of Lithospermum erythrorhizon, down-regulates the expression of steroid sulfatase genes in breast cancer cells
Cancer Lett.
284
47-54
2009
Homo sapiens
Manually annotated by BRENDA team
Ahmed, V.; Liu, Y.; Taylor, S.
Multiple pathways for the irreversible inhibition of steroid sulfatase with quinone methide-generating suicide inhibitors
ChemBioChem
10
1457-1461
2009
Homo sapiens
Manually annotated by BRENDA team
Gonzalez-Huerta, L.; Mendiola-Jimenez, J.; Del Moral-Stevenel, M.; Rivera-Vega, M.; Cuevas-Covarrubias, S.
Atypical X-linked ichthyosis in a patient with a large deletion involving the steroid sulfatase (STS) gene
Int. J. Dermatol.
48
142-144
2009
Homo sapiens
Manually annotated by BRENDA team
Zhang, Y.; Li, P.P.
Shu-Gan-Liang-Xue Decoction, a Chinese herbal formula, down-regulates the expression of steroid sulfatase genes in human breast carcinoma MCF-7 cells
J. Ethnopharmacol.
127
620-624
2010
Homo sapiens
Manually annotated by BRENDA team
Woo, L.W.; Jackson, T.; Putey, A.; Cozier, G.; Leonard, P.; Acharya, K.R.; Chander, S.K.; Purohit, A.; Reed, M.J.; Potter, B.V.
Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template
J. Med. Chem.
53
2155-2170
2010
Homo sapiens
Manually annotated by BRENDA team
Nardi, A.; Pomari, E.; Zambon, D.; Belvedere, P.; Colombo, L.; Dalla Valle, L.
Transcriptional control of human steroid sulfatase
J. Steroid Biochem. Mol. Biol.
115
68-74
2009
Homo sapiens (P08842), Homo sapiens
Manually annotated by BRENDA team
Fournier, M.A.; Poirier, D.
Estrogen formation in endometrial and cervix cancer cell lines: involvement of aromatase, steroid sulfatase and 17beta-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12)
Mol. Cell. Endocrinol.
301
142-145
2009
Homo sapiens
Manually annotated by BRENDA team
Marcos, J.; Craig, W.Y.; Palomaki, G.E.; Kloza, E.M.; Haddow, J.E.; Roberson, M.; Bradley, L.A.; Shackleton, C.H.
Maternal urine and serum steroid measurements to identify steroid sulfatase deficiency (STSD) in second trimester pregnancies
Prenat. Diagn.
29
771-780
2009
Homo sapiens
Manually annotated by BRENDA team
Langlois, S.; Armstrong, L.; Gall, K.; Hulait, G.; Livingston, J.; Nelson, T.; Power, P.; Pugash, D.; Siciliano, D.; Steinraths, M.; Mattman, A.
Steroid sulfatase deficiency and contiguous gene deletion syndrome amongst pregnant patients with low serum unconjugated estriols
Prenat. Diagn.
29
966-974
2009
Homo sapiens
Manually annotated by BRENDA team
Wang, M.; Mickens, J.; Gao, M.; Miller, K.D.; Sledge, G.W.; Hutchins, G.D.; Zheng, Q.H.
Design and synthesis of carbon-11-labeled dual aromatase-steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expression in breast cancer
Steroids
74
896-905
2009
Homo sapiens
Manually annotated by BRENDA team
Woo, L.W.; Ganeshapillai, D.; Thomas, M.P.; Sutcliffe, O.B.; Malini, B.; Mahon, M.F.; Purohit, A.; Potter, B.V.
Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor irosustat (STX64, BN83495)
ChemMedChem
6
2019-2034
2011
Homo sapiens
Manually annotated by BRENDA team
Shah, K.; Cartledge, T.; Ahmed, S.
Estrone sulfatase, a target enzyme in the treatment of hormone-dependent breast cancer
Drugs Future
35
729-745
2010
Homo sapiens
-
Manually annotated by BRENDA team
Fournier, D.; Poirier, D.
Chemical synthesis and evaluation of 17alpha-alkylated derivatives of estradiol as inhibitors of steroid sulfatase
Eur. J. Med. Chem.
46
4227-4237
2011
Homo sapiens
Manually annotated by BRENDA team
Suzuki, T.; Miki, Y.; Nakamura, Y.; Ito, K.; Sasano, H.
Steroid sulfatase and estrogen sulfotransferase in human carcinomas
Mol. Cell. Endocrinol.
340
148-153
2011
Homo sapiens
Manually annotated by BRENDA team
Purohit, A.; Woo, L.W.; Potter, B.V.
Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism
Mol. Cell. Endocrinol.
340
154-160
2011
Homo sapiens
Manually annotated by BRENDA team
Phan, C.M.; Liu, Y.; Kim, B.M.; Mostafa, Y.; Taylor, S.D.
Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives
Bioorg. Med. Chem.
19
5999-6005
2011
Homo sapiens
Manually annotated by BRENDA team
Ganeshapillai, D.; Woo, L.W.L.; Thomas, M.P.; Purohit, A.; Potter, B.V.L.
C-3- and C-4-substituted bicyclic coumarin sulfamates as potent steroid sulfatase inhibitors
ACS omega
3
10748-10772
2018
Homo sapiens
Manually annotated by BRENDA team
Mostafa, Y.A.; Kralt, B.; Rao, P.P.; Taylor, S.D.
A-ring substituted 17beta-arylsulfonamides of 17beta-aminoestra-1,3,5(10)-trien-3-ol as highly potent reversible inhibitors of steroid sulfatase
Bioorg. Med. Chem.
23
5681-5692
2015
Homo sapiens (P08842)
Manually annotated by BRENDA team
El-Gamal, M.I.; Semreen, M.H.; Foster, P.A.; Potter, B.V.
Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors
Bioorg. Med. Chem.
24
2762-2767
2016
Homo sapiens (P08842)
Manually annotated by BRENDA team
Dasko, M.; Przybylowska, M.; Rachon, J.; Maslyk, M.; Kubinski, K.; Misiak, M.; Skladanowski, A.; Demkowicz, S.
Synthesis and biological evaluation of fluorinated N-benzoyl and N-phenylacetoyl derivatives of 3-(4-aminophenyl)-coumarin-7-O-sulfamate as steroid sulfatase inhibitors
Eur. J. Med. Chem.
128
79-87
2017
Homo sapiens (P08842), Homo sapiens
Manually annotated by BRENDA team
Salah, M.; Abdelsamie, A.S.; Frotscher, M.
First dual inhibitors of steroid sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) designed multiple ligands as novel potential therapeutics for estrogen-dependent diseases
J. Med. Chem.
60
4086-4092
2017
Homo sapiens (P08842)
Manually annotated by BRENDA team
Gibson, D.A.; Foster, P.A.; Simitsidellis, I.; Critchley, H.O.D.; Kelepouri, O.; Collins, F.; Saunders, P.T.K.
Sulfation pathways A role for steroid sulphatase in intracrine regulation of endometrial decidualisation
J. Mol. Endocrinol.
61
M57-M65
2018
Homo sapiens (P08842), Homo sapiens
Manually annotated by BRENDA team
Kurogi, K.; Yoshihama, M.; Williams, F.E.; Kenmochi, N.; Sakakibara, Y.; Suiko, M.; Liu, M.C.
Identification of zebrafish steroid sulfatase and comparative analysis of the enzymatic properties with human steroid sulfatase
J. Steroid Biochem. Mol. Biol.
185
110-117
2019
Danio rerio (F1QB82), Danio rerio, Homo sapiens (P08842), Homo sapiens
Manually annotated by BRENDA team
Dias, N.J.; Selcer, K.W.
Steroid sulfatase in the human MG-63 preosteoblastic cell line Antagonistic regulation by glucocorticoids and NFkappaB
Mol. Cell. Endocrinol.
420
85-96
2016
Homo sapiens (P08842), Homo sapiens
Manually annotated by BRENDA team